Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

NEXT STORY
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
PREV STORY
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NeoGenomics Schedules its Second Quarter Earnings Release for July 24, 2018

FT. MYERS, Fla., July 02, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ:NEO), a leading ...

author_avatar
NASDAQ Market News

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02

Extends IP protection of TG02 in the US until 09.12.2034Oslo, 3 October 2017: Targovax ...

author_avatar
NASDAQ Market News

US Department of Defense Reports Travelan Protects Against Shigella in Primates

Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented ...

author_avatar
NASDAQ Market News